Abstract:A large number of epidemiological and clinical studies have shown that elevated lipoprotein(a) [Lp(a)] is closely associated with atherosclerotic cardiovascular disease(ASCVD), and that Lp(a) remains a risk factor for the development of ASCVD even when plasma low-density lipoprotein cholesterol(LDL-C) is effectively reduced. Related studies have also confirmed that elevated Lp(a) increases the incidence of major adverse cardiovascular events(MACE). There are still many uncertainties regarding the pathogenic mechanisms of Lp(a), and new therapies capable of effectively lowering Lp(a) levels are in the later stages of clinical development. This article aims to review the relationship between Lp(a) and ASCVD, along with related treatments, in order to provide new ideas for the treatment of ASCVD.
Key words:Atherosclerotic cardiovascular disease ; Lipoprotein a ; Major adverse cardiovascular events ; Mechanism ; Treatments
Funding: Natural Science Foundation of Inner Mongolia Autonomous Region(2021MS08148)
Author:Jia Haiyu,E-mail:nmjiahaiyu@qq.com;